Caidya

Caidya

Global CRO delivering end-to-end clinical development

Overview

Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.

About Caidya

Simplify's Rating
Why Caidya is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Consulting

Enterprise Software

Healthcare

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$322.2M

Headquarters

Morrisville, North Carolina

Founded

2003

Get referred to Caidya

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Rubicon Founders’ $165 million investment funds expansion and strategic acquisitions.
  • February 2026 European hiring and June 2026 combination signal active commercial acceleration.
  • Simbec-Orion’s 48-bed Phase I unit expands early-phase revenue and sponsor stickiness.

What critics are saying

  • June 2026 Simbec-Orion integration can distract teams and delay client deliveries through 2027.
  • China CRO competition is shifting toward capability battles, compressing margins and win rates.
  • If integration slips, larger CROs like ICON and Fortrea poach sponsors and talent.

What makes Caidya unique

  • June 2026 Simbec-Orion combination adds phase I units and Europe-to-China coverage.
  • Caidya pairs China regulatory expertise with global execution across Americas, Europe, APAC.
  • Michael Clay’s February 2026 COO hire strengthens delivery across 50-country clinical programs.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$322.2M

Above

Industry Average

Funded Over

10 Rounds

Growth Equity VC funding comparison data is currently unavailable. We're working to provide this information soon!
Growth Equity VC Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

-38%
Business Wire
Jul 1st, 2026
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution....

Associated Press
Feb 17th, 2026
Caidya appoints Michael Clay as COO to strengthen global clinical trial operations across Asia-Pacific

Caidya, a global clinical research organisation, has appointed Michael Clay as chief operating officer. Clay will oversee global operational delivery, client engagement and execution strategy across the US, Europe and Asia-Pacific. Clay brings extensive experience leading global clinical programmes across more than 60 countries, with particular expertise in Asia-Pacific operations. Most recently, he served as senior vice president of Global Project Delivery at Fortrea, where he managed over 500 global clinical trials. The appointment strengthens Caidya's operational capabilities, particularly in China and the broader APAC region. Caidya operates in more than 20 countries and conducts studies across over 50 countries, focusing on complex therapeutic areas including oncology, haematology and rare diseases.

Business Wire
Jan 16th, 2025
Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

FinSMEs
Jul 10th, 2021
dMed-Clinipace Closes US$50M Series C+ Financing

dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed by Rock Springs Capital and Superstring Capital. They joined Series C lead investor Fidelity Management and Research Company LLC as well as other new […]

WRAL TechWire
Jul 7th, 2021
Recently merged CRO Clinipace raises $50M in new funding

MORRISVILLE – Clinical research firm Clinipace, which recently merged with Shanghai-based dMed, has closed on $50 million in new funding from three primary backers.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Caidya right now.

Find jobs on Simplify and start your career today

We update Caidya's jobs every few hours, so check again soon! Browse all jobs →